Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/10819
Title: Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study
Authors: Demirci, A.
Alkış, N.
Dane, F.
Durnalı, A.
Yazıcı, Ö.K.
Rzayev, R.
Kaya, S.
Keywords: breast cancer
medical oncology
pharmacy
anthracycline
aromatase inhibitor
cyclophosphamide
docetaxel
fluorouracil
gonadorelin associated peptide derivative
tamoxifen
trastuzumab
gonadorelin
adjuvant therapy
adult
Article
cancer grading
cancer patient
cancer survival
controlled study
demography
disease free survival
early cancer
female
follow up
hormone sensitivity
human
major clinical study
multiple cycle treatment
overall survival
premenopause
priority journal
retrospective study
survival time
treatment duration
Turkey (republic)
breast tumor
middle aged
mortality
oncology
young adult
Adult
Breast Neoplasms
Disease-Free Survival
Female
Gonadotropin-Releasing Hormone
Humans
Medical Oncology
Middle Aged
Retrospective Studies
Young Adult
Publisher: Blackwell Publishing Ltd
Abstract: Aim: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. Methods: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. Results: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1–87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4–12 months (Group A), 13–24 months (Group B) and ?25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 ± 30.3 (range, 4–188) months. The OS in patients ?35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000). Conclusion: There is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use. © 2017 John Wiley & Sons Australia, Ltd
URI: https://hdl.handle.net/11499/10819
https://doi.org/10.1111/ajco.12685
ISSN: 1743-7555
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Feb 24, 2024

WEB OF SCIENCETM
Citations

1
checked on Sep 24, 2024

Page view(s)

32
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.